LTF and neoplasm: By using lactoferrin-modified targeted liposomal system (LF-Lipo) to co-deliver ecognizedt and JQ1, binding with LRP-1 receptors on tumor cells and TAMs can reduce lactate production, repolarize M2 phenotype TAMs, and enhance CD8+ T cell antitumor and anti-angiogenesis responses (159).